Legal Briefs: Courts On Exclusivity; Namenda ‘Hard Switch’ Deemed Coercive; Acorda Fights Bass Patent Petition
FDA’s active moiety rationale for denying Vascepa five years exclusivity is rejected by district court; Actavis strategy to protect Namenda franchise meets another hurdle; Acorda challenges ‘improper purpose’ of Bass IPR petition.
You may also be interested in...
In joint complaint, the FTC and New York Attorney General allege scheme to block generic Daraprim and maintain exorbitant list price; they cite hundreds of emails the incarcerated Shkreli has exchanged with co-defendant in last six months.
Direct purchasers' $750m settlement with Allergan is at least the second involving product hopping claims; only one DOJ settlement surpassed this amount in the past year.
Legislation is targeting a wide range of patent practices, from product hopping to patent infringement settlements and inter partes review.